SCHEMBL1335258

SCHEMBL1335258

COCCOCC(=O)Nc1ccc(-c2ccc(NC(=O)Nc3cccc(C)c3)cc2)c2c1C(=O)NC2

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 20/20 0.73
FLT3 P36888 3/20 0.60
ROCK2 O75116 2/20 0.60
RET P07949 2/20 0.60
FLT1 P17948 2/20 0.60
EPHA2 P29317 2/20 0.60
FLT4 P35916 2/20 0.60
AURKB Q96GD4 2/20 0.60
PLK4 O00444 1/20 0.60
AURKA O14965 1/20 0.60
PRKD3 O94806 1/20 0.60
MAP4K4 O95819 1/20 0.60
NTRK1 P04629 1/20 0.60
LCK P06239 1/20 0.60
CSF1R P07333 1/20 0.60
MET P08581 1/20 0.60
PIM1 P11309 1/20 0.60
RPS6KB1 P23443 1/20 0.60
BLK P51451 1/20 0.60
CSNK2A1 P68400 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1334442 0.85 KDR (1.00) KDRFLT3ROCK2RETFLT1
SCHEMBL1335237 0.84 KDR (1.00) KDRFLT3ROCK2RETFLT1
SCHEMBL1333691 0.83 KDR (1.00) KDRFLT3ROCK2RETFLT1
SCHEMBL1333349 0.83 KDR (0.77) KDRFLT3ROCK2RETFLT1
SCHEMBL1335385 0.82 KDR (1.00) KDRFLT3ROCK2RETFLT1
SCHEMBL1335465 0.81 KDR (1.00) KDRFLT3ROCK2RETFLT1
SCHEMBL5746455 0.80 KDR (0.80) KDRFLT3ROCK2RETFLT1
SCHEMBL1333748 0.80 KDR (0.80) KDRFLT3ROCK2RETFLT1
SCHEMBL3598545 0.79 KDR (0.79) KDRFLT3ROCK2RETFLT1
SCHEMBL1333256 0.79 KDR (1.00) KDRFLT3ROCK2RETFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060287370-A1 Isoindolinone kinase inhibitors CURTIN MICHAEL L 2006-12-21 US claimed
US-7129260-B2 Isoindolinone kinase inhibitors ABBOTT LABORATORIES (US) 2006-10-31 US claimed
US-20050026976-A1 Isoindolinone kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US claimed
US-20110275630-A1 ISOINDOLINONE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2011-11-10 US disclosed
US-20100076051-A1 ISOINDOLINONE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-25 US disclosed
US-7129260-B2 Isoindolinone kinase inhibitors ABBOTT LABORATORIES (US) 2006-10-31 US disclosed
US-20050026976-A1 Isoindolinone kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287370-A1 Isoindolinone kinase inhibitors ABL1, LCK, MAP3K7 KDR 527/4885FLT3 165/4885ROCK2 264/4885
US-20050026976-A1 Isoindolinone kinase inhibitors ABL1, LCK, MAP3K7 KDR 527/4885FLT3 165/4885ROCK2 264/4885
US-20100076051-A1 ISOINDOLINONE KINASE INHIBITORS ABL1, LCK, MAP3K7 KDR 527/4885FLT3 165/4885ROCK2 264/4885
US-20110275630-A1 ISOINDOLINONE KINASE INHIBITORS MAP3K7, MAP3K5, MAP3K20 KDR 909/4885FLT3 491/4885ROCK2 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.